8-K: Genprex Faces Nasdaq Delisting Threat

Genprex, Inc. received a Nasdaq delisting notice due to non-compliance with minimum stockholders' equity and bid price requirements, but has requested a hearing to appeal.

Summary

• Genprex, Inc. received a letter from Nasdaq on August 19, 2025, indicating non-compliance with the minimum stockholders' equity requirement for continued listing.
• The company's stockholders' equity was $1,391,195 as of June 30, 2025, which is below Nasdaq's required minimum of $2.5 million.
• Genprex also failed to meet alternative compliance standards related to market value of listed securities or net income from continuing operations.
• This non-compliance serves as an additional and separate basis for delisting the company's securities from Nasdaq.
• Previously, on August 12, 2025, Nasdaq notified the company of non-compliance with the $1.00 minimum bid price requirement, which was not regained by the August 6, 2025 deadline.
• The company was not eligible for a second 180-day extension for the bid price requirement due to not meeting Nasdaq's $5,000,000 minimum stockholders' equity initial listing requirement.
• Genprex timely requested a hearing before the Nasdaq Hearings Panel on August 19, 2025.
• The request for a hearing has stayed any suspension or delisting action by Nasdaq pending the hearing and any potential extension period granted by the Panel.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the company's non-compliance with two critical Nasdaq listing requirements and the imminent threat of delisting. While the company has requested a hearing, the underlying financial issues (low equity, low bid price) remain severe, and there is no guarantee of regaining compliance or avoiding delisting.

Positives

• Genprex has timely requested a hearing before the Nasdaq Hearings Panel, which temporarily stays any suspension or delisting action.
• The company intends to present a plan to regain compliance with all Nasdaq listing requirements.

Negatives

• Genprex is not in compliance with Nasdaq's minimum stockholders' equity requirement, holding $1,391,195 against a $2.5 million minimum.
• The company failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the August 6, 2025 deadline.
• Genprex did not meet alternative compliance standards for market value of listed securities or net income from continuing operations.
• The company is ineligible for a second 180-day extension for the bid price requirement due to insufficient stockholders' equity.

Risks

• There is no assurance that the Nasdaq Hearings Panel will grant Genprex's request for continued listing.
• The company may not be able to evidence compliance with the Minimum Stockholders Equity Requirement, the Bid Price Requirement, and other Nasdaq listing requirements within any extension period granted.
• Failure to regain compliance could lead to the delisting of the company's common stock from The Nasdaq Capital Market.

Future Outlook

Genprex intends to request an extension from the Nasdaq Hearings Panel to regain compliance with both the bid price and minimum stockholders' equity requirements. The company plans to present its views on these deficiencies and submit a plan to regain compliance. However, there is no assurance that the Panel will grant the request or that the company will successfully regain and maintain compliance within any granted extension period.

Management Comments

• The company intends to request an extension from the Nasdaq Hearings Panel to evidence compliance with the Bid Price Requirement and the Minimum Stockholders Equity Requirement.
• The company plans to present its views with respect to these deficiencies and submit a plan to regain compliance with all applicable requirements for continued listing on Nasdaq.

Industry Context

Delisting notices from major exchanges like Nasdaq are significant events for publicly traded companies, often signaling financial distress or operational challenges. For biotechnology companies, maintaining exchange listing is crucial for access to capital and investor visibility, as delisting can severely impact liquidity and valuation, making it harder to fund research and development.

Stakeholder Impact

• Shareholders face significant risk of share price depreciation and reduced liquidity if the company is delisted from Nasdaq.
• Employees may face uncertainty regarding the company's future and potential operational changes if delisting occurs.
• Potential investors may be deterred by the delisting threat, impacting the company's ability to raise future capital.

Next Steps

• Genprex will attend a hearing before the Nasdaq Hearings Panel.
• The company intends to request an extension from the Panel to regain compliance with listing requirements.
• Genprex plans to present its views on the deficiencies and submit a plan to regain compliance.
• The company will continue to take definitive steps to evidence compliance with Nasdaq listing requirements.

Key Dates

Recommendation

The company is in severe non-compliance with two fundamental Nasdaq listing rules, including a significant deficiency in stockholders' equity and a prolonged failure to meet the minimum bid price. While a hearing has been requested, there is no assurance of a favorable outcome or the ability to regain compliance. Delisting would severely impair liquidity and investor confidence, making the stock a high-risk proposition with significant downside potential.

Keywords

Nasdaq, delisting, stockholders equity, bid price, compliance, 8-K, Genprex, GNPX, listing requirements